Cargando…

M22. IGG ANTIBODIES TO TOXOPLASMA GONDII ARE ASSOCIATED WITH INCREASED LONG-TERM RISK FOR PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS

BACKGROUND: The prevalence of antibodies to Toxoplasma gondii, a ubiquitous parasitic protozoan causing the infectious disease toxoplasmosis, is increased in patients with psychotic disorders compared to the general population. We have previously shown that antibody titers for T.gondii correlate wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Maximus, Burkhardt, Eva, Yung, Alison, Nelson, Barnaby, Francey, Shona, Lin, Ashleigh, Wood, Stephen, Thompson, Andrew, Berger, Gregor, Philipps, Lisa, Harrington, Suzy, McGorry, Patrick, Yolken, Robert, Amminger, G Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234247/ http://dx.doi.org/10.1093/schbul/sbaa030.334

Ejemplares similares

S8. RELATIONSHIP BETWEEN ALLOSTATIC LOAD AND POOR FUNCTIONAL CAPACITY IN YOUTH AT ULTRA-HIGH RISK FOR PSYCHOSIS
por: Berger, Maximus, et al.
Publicado: (2018)

Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research
por: Nelson, Barnaby, et al.
Publicado: (2018)

M21. THE STEP TRIAL: A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMISED TRIAL (SMART) OF INTERVENTIONS FOR PATIENTS AT ULTRA-HIGH RISK OF PSYCHOSIS - STUDY RATIONALE, DESIGN AND BASELINE DATA
por: Nelson, Barnaby, et al.
Publicado: (2020)

Persistent negative symptoms in individuals at Ultra High Risk for psychosis
por: Yung, Alison R., et al.
Publicado: (2019)

Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis
por: Mechelli, Andrea, et al.
Publicado: (2017)

The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research
por: Brown, Ellie, et al.
Publicado: (2020)

T119. CAN SOME YOUNG PEOPLE RECOVER FROM FIRST-EPISODE PSYCHOSIS WITH INTEGRATED PSYCHOSOCIAL TREATMENT WITHOUT ANTIPSYCHOTIC MEDICATIONS? AN RCT TO ASSESS RISKS, BENEFITS, AND RANGE OF OUTCOMES
por: McGorry, Patrick, et al.
Publicado: (2018)

Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
por: Nelson, Barnaby, et al.
Publicado: (2020)

T30. TIPPING POINTS – PREDICTING TRANSITIONS TO PSYCHOSIS IN AT-RISK YOUNG PEOPLE
por: Hartmann, Jessica A, et al.
Publicado: (2018)

Evidence of increased exposure to Toxoplasma gondii in individuals with recent onset psychosis but not with established schizophrenia
por: Yolken, Robert, et al.
Publicado: (2017)

M20. CYTOKINE LEVELS THROUGHOUT PREGNANCY AND RISK FOR PSYCHOSIS IN ADULT OFFSPRING: EARLY PREGNANCY MATTERS
por: Allswede, Dana, et al.
Publicado: (2020)

Erythrocyte glutathione levels as long-term predictor of transition to psychosis
por: Lavoie, S, et al.
Publicado: (2017)

T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL
por: Schlögelhofer, Monika, et al.
Publicado: (2020)

Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis
por: Berger, Gregor E., et al.
Publicado: (2016)

Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis
por: Bousman, C A, et al.
Publicado: (2013)

M195. LATENT STRUCTURE OF NEGATIVE SYMPTOMS IN EARLY PSYCHOSIS AND CLINICAL HIGH-RISK FOR PSYCHOSIS
por: Chi Yiu Wong, Sandra, et al.
Publicado: (2020)

White matter integrity in individuals at ultra-high risk for psychosis: a systematic review and discussion of the role of polyunsaturated fatty acids
por: Vijayakumar, Nandita, et al.
Publicado: (2016)

Early Intervention in Psychosis: Obvious, Effective, Overdue
por: McGorry, Patrick D.
Publicado: (2015)

Cognitive ability and metabolic physical health in first-episode psychosis
por: Whitson, Sarah, et al.
Publicado: (2021)

S166. EFFECTIVE CONNECTIVITY OF FRONTOSTRIATAL SYSTEMS IN FIRST-EPISODE PSYCHOSIS
por: Sabaroedin, Kristina, et al.
Publicado: (2020)

Editorial: Clinical High Risk for Psychosis: From Epidemiological Findings to Neurobiological Underpinnings of Treatment Response and Outcome
por: Michel, Chantal, et al.
Publicado: (2021)

Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
por: Cheng, Nicholas, et al.
Publicado: (2022)

Gradients of striatal function in antipsychotic-free first-episode psychosis and schizotypy
por: Oldehinkel, Marianne, et al.
Publicado: (2023)

M110. PREDICTING RISK OF PSYCHOSIS IN A GENERAL POPULATION SAMPLE
por: Kounali, Daphne, et al.
Publicado: (2020)

Discharge destinations for young people with a first episode of psychosis after attending an early intervention for psychosis service
por: O’Donoghue, Brian, et al.
Publicado: (2023)

Frontostriatothalamic effective connectivity and dopaminergic function in the psychosis continuum
por: Sabaroedin, Kristina, et al.
Publicado: (2022)

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
por: Amminger, G P, et al.
Publicado: (2015)

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
por: Föcking, Melanie, et al.
Publicado: (2016)

Toxoplasma gondii and Schizophrenia
por: Torrey, E. Fuller, et al.
Publicado: (2003)

M118. FACTOR STRUCTURE OF THE CLINICIAN-RATED DIMENSION OF PSYCHOSIS SYMPTOM SEVERITY IN PATIENTS WITH EARLY PSYCHOSIS
por: Lee, Kyuyoung, et al.
Publicado: (2020)

Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First-Episode Psychosis and Low Risk of Self-harm or Aggression: A Secondary Analysis of a Randomized Clinical Trial
por: Chopra, Sidhant, et al.
Publicado: (2021)

Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
por: Susai, Subash Raj, et al.
Publicado: (2022)

4.3 ENHANCING SOCIAL FUNCTIONING AND LONG-TERM RECOVERY IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS (FEP) AND YOUNG PEOPLE AT ULTRA HIGH RISK (UHR) FOR PSYCHOSIS: A NOVEL ONLINE SOCIAL THERAPY APPROACH
por: Alvarez-Jimenez, Mario, et al.
Publicado: (2018)

Correlates of substance use in a large naturalistic cohort of young people with early and emerging psychosis
por: El-Hage, D., et al.
Publicado: (2023)

A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial
por: McGorry, Patrick D., et al.
Publicado: (2023)

M136. PSYCHOSIS POLYRISK SCORE (PPS): IMPROVING DETECTION OF INDIVIDUALS AT-RISK AND PREDICTION OF CLINICAL OUTCOMES
por: Oliver, Dominic, et al.
Publicado: (2020)

Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective
por: Ong, Hui Lin, et al.
Publicado: (2021)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

“Attenuated psychotic symptoms syndrome” as a risk syndrome of psychosis, diagnosis in DSM-V: The debate
por: Shrivastava, Amresh, et al.
Publicado: (2011)

M98. IS THERE A DEVELOPMENTAL TRAUMAGENIC PHENOTYPE OF PSYCHOSIS?
por: Bloomfield, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7bgun30svuu97brm5an28915i8